Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Trends Cancer. 2021 Apr 14;7(8):714–730. doi: 10.1016/j.trecan.2021.03.001

Figure 2. Biguanides enhance the efficacy of chemotherapy or targeted therapy to prevent tumor relapse by targeting tumor heterogeneity.

Figure 2.

Tumor heterogeneity contributes to drug resistance and the use of biguanides prevents tumor relapse by targeting certain OXPHOS-addicting sub-populations of cancer cells within the tumor that are resistant to conventional therapies such as cancer stem cells or slow-cycling cell types (indicated in red).